RxDoctor Payments Data

Charles Beamon, MD

Urology · Fredericksburg, VANPI 1194996686

Payments from drug & device makers

$7,753in general payments, 2019–2025

Across 361 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$922
  • Medtronic$568
  • Pfizer$459
  • Sumitomo Pharma America, Inc.$378
  • Urogen Pharma, Inc.$376
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$6,93889%
  • Education$81511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,753 in reported general payments places this provider in the 65th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$729,992
Medicare patients
1,402
Services billed
10,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron169$186,858
MyrbetriqMirabegron156$159,215
Mirabegron ErMirabegron19$9,178
Tamsulosin Hcl558$8,480
NitrofurantoinNitrofurantoin Macrocrystal162$4,314
Tolterodine Tartrate ErTolterodine Tartrate35$3,598
Fesoterodine Fumarate ErFesoterodine Fumarate23$2,367
Testosterone12$2,274
Tadalafil35$2,091
Oxybutynin Chloride ErOxybutynin Chloride61$2,010
Silodosin14$1,558
Trospium Chloride11$1,145
Finasteride89$876
Cephalexin75$746
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$378$186,858169 claims
Astellas Pharma US IncMyrbetriq$1,137$159,215156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 300 urology providers in Virginia.

Other urology in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →